Oppenheimer Holdings, Inc. Analysts Give Eiger BioPharmaceuticals, Inc. (EIGR) a $34.00 Price Target
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) received a $34.00 price objective from research analysts at Oppenheimer Holdings, Inc. in a report issued on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target would suggest a potential upside of 165.63% from the stock’s previous close.
EIGR has been the topic of several other reports. Roth Capital initiated coverage on shares of Eiger BioPharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research lowered shares of Eiger BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. ValuEngine upgraded shares of Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. BTIG Research initiated coverage on shares of Eiger BioPharmaceuticals in a research note on Friday, July 14th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $36.00 price target on shares of Eiger BioPharmaceuticals in a research note on Tuesday, August 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.43.
Shares of Eiger BioPharmaceuticals (EIGR) traded down 5.273% during midday trading on Monday, reaching $12.125. 118,107 shares of the company were exchanged. The stock has a 50-day moving average price of $11.38 and a 200 day moving average price of $8.76. The company’s market capitalization is $101.45 million. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $14.56.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.05). Equities research analysts expect that Eiger BioPharmaceuticals will post ($5.21) EPS for the current fiscal year.
In other news, Director Jeffrey S. Glenn purchased 15,000 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was bought at an average price of $9.53 per share, with a total value of $142,950.00. Following the acquisition, the director now owns 31,355 shares in the company, valued at approximately $298,813.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 28.80% of the company’s stock.
Several institutional investors have recently modified their holdings of EIGR. Interwest Venture Management Co. bought a new stake in shares of Eiger BioPharmaceuticals during the 4th quarter worth approximately $18,635,000. Vivo Capital LLC acquired a new position in Eiger BioPharmaceuticals during the 1st quarter worth approximately $26,825,000. Sabby Management LLC acquired a new position in Eiger BioPharmaceuticals during the 1st quarter worth approximately $4,354,000. Sphera Funds Management LTD. increased its position in Eiger BioPharmaceuticals by 147.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 373,568 shares of the biotechnology company’s stock worth $5,002,000 after purchasing an additional 222,852 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in Eiger BioPharmaceuticals during the 4th quarter worth approximately $1,836,000. 59.94% of the stock is owned by institutional investors.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.